Gritstone bio, Inc. (GRTS) Stock

About Gritstone bio, Inc.

Gritstone bio, Inc. is a clinical-stage biotechnology company focused on pioneering immunotherapies to address various types of cancer and infectious diseases. Its primary product candidate, GRANITE, is a neoantigen-based immunotherapy designed to treat a range of solid tumors, specifically including metastatic non-small cell lung cancer, gastroesophageal, bladder, and microsatellite stable colorectal cancers. Gritstone bio is also advancing SLATE, an off-the-shelf immunotherapy candidate aimed at common solid tumors such as metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and those with shared neoantigens. Furthermore, the company is developing CORAL, a SARS-CoV-2 vaccine platform intended to provide broader and more robust immunity against variants by delivering both spike and additional SARS-CoV-2 T cell epitopes. It is also working on a therapeutic vaccine candidate focused on treating and potentially curing human immunodeficiency virus (HIV) infection. Gritstone bio maintains key partnerships, including a strategic collaboration with bluebird bio, Inc., a collaboration agreement with Gilead Sciences, Inc., and a license agreement with Genevant Sciences GmbH. Founded in 2015 and headquartered in Emeryville, California, the company operated as Gritstone Oncology, Inc. until its rebranding to Gritstone bio, Inc. in May 2021.

Gritstone bio, Inc. is headquartered in US.

Gritstone bio, Inc. (GRTS) stock trades at $0.03 with a market capitalization of $3.80M. The stock is valued at a price-to-earnings (P/E) ratio of -0.03, price-to-book of 0.07, price-to-sales of 2.86. Over the past 52 weeks the stock has ranged between $0.03 and $3.17, and currently trades 99.1% below its 52-week high.

On profitability, Gritstone bio, Inc. generates a return on equity (ROE) of -124.41%, return on capital employed of -102.79%, an operating margin of -15500.00%, a net profit margin of -13800.00%.

Official website: gritstonebio.com